Kymab appoints Dr Martin Nicklasson as Non-Executive Chair

Kymab Group Limited (“Kymab”), a leading human monoclonal antibody biopharmaceutical group, announces the appointment of Dr Martin Nicklasson as Non-Executive Chair. Dr.Nicklasson has held a number of senior positions at AstraZeneca Plc including Executive Vice President (“EVP”) of Global Marketing and Business Development and EVP of Global Drug Development. He was CEO of Biovitrum AB and Swedish Orphan Biovitrum AB and is currently Chair of the boards of Orexo AB and Zealand Pharma A/S.